PF-Atlas › Clinical Trials › NCT02951195
A Study Evaluating the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis
VX-152 · Phase 2
Registry ID
NCT02951195
Phase
Phase 2
Status
Completed
Drug / intervention
VX-152
Sponsor
Vertex Pharmaceuticals Incorporated
Start
2016-11
Enrollment
80
Locations
16
About this trial
This is a Phase 2, randomized, double blind, placebo and active-controlled, parallel group, multicenter study designed to evaluate the safety and tolerability of VX-152 in Triple Combination (TC) with tezacaftor (TEZ; VX-661) and ivacaftor (IVA; VX-770) in subjects with cystic fibrosis (CF) who are heterozygous for the F508del mutation and a minimal function (MF) CFTR mutation not likely to respond to TEZ and/or IVA therapy (F508del/MF), or who are homozygous for the F508del mutation of the CF transmembrane conductance regulator (CFTR) gene (F508del/F508del).
Explore related
Medical disclaimer. This page summarizes public trial data for NCT02951195 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.